Key result
PARP1 inhibitors attenuated status epilepticus-induced neuronal death in CA1 and CA3 regions but aggravated astroglial death in the dentate gyrus and CA3 stratum lucidum.
Population
Male Sprague-Dawley rats, 9-11 weeks old, subjected to pilocarpine-induced status epilepticus in vivo…
Comparison
PARP1 inhibitors administered via… vs Vehicle infusion prior to pilocarpine-induced…
Design
Preclinical
Follow-up
Up to 4 weeks after status epilepticus
Authors
Loading...
Suggests cell-specific PARP1 targeting may optimize neuroprotection in SE models; leaves open clinical translation pending human studies.
p-value: p=<0.05
Cellular-specific PARP1 activation and degradation distinctly modulate regional-specific neuronal damage and astroglial death following status epilepticus independently of hemodynamics.
Kim et al. (2014) studied Status epilepticus (n=135). PARP1 inhibitors (PJ-34 and DPQ) vs. Vehicle (saline) was evaluated on Neuronal death in CA1 and CA3 regions (FJB-positive degenerative neurons/mm3) (p=<0.05). PARP1 inhibitors attenuated status epilepticus-induced neuronal death in CA1 and CA3 regions but aggravated astroglial death in the dentate gyrus and CA3 stratum lucidum.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: